Article Text
PDF
Statistics from Altmetric.com
Q In women who are menopausal, is paroxetine controlled release (CR) effective and tolerable for treating vasomotor symptoms?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Endocrine ★★★★★☆☆
METHODS
Design:
randomised placebo controlled trial.
Allocation:
{concealed*}†.
Blinding:
blinded {patients, healthcare providers, data collectors, outcome assessors}†.*
Follow up period:
6 weeks.
Setting:
17 sites (including urban, suburban, and rural clinics) in the US.
Patients:
165 women ⩾18 years of age (mean age 54 y) who were menopausal (defined as amenorrhoea for ⩾12 consecutive mo, amenorrhoea for 6 mo and meeting the biochemical criteria for menopause, or history of bilateral oophorectomy ⩾6 wks before screening), experienced ⩾2–3 daily hot flashes or ⩾14 bothersome hot flashes/week, had discontinued hormone replacement therapy for ⩾6 weeks, and had discontinued psychotropic drugs for 2–12 weeks (specified for class of …
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Linked Articles
- Glossary